{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T01:27:00Z","timestamp":1794446820016,"version":"4.9.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U24CA231858"],"award-info":[{"award-number":["U24CA231858"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01CA240589"],"award-info":[{"award-number":["R01CA240589"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01CA276540"],"award-info":[{"award-number":["R01CA276540"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"crossref","award":["RSG-18-006-01-CC"],"award-info":[{"award-number":["RSG-18-006-01-CC"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Cancer Prevention and Research Institute of Texas,United States","award":["CPRIT RR16000"],"award-info":[{"award-number":["CPRIT RR16000"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Syst Biol Appl"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We seek to establish a parsimonious mathematical framework for understanding the interaction and dynamics of the response of pancreatic cancer to the NGC triple chemotherapy regimen (mNab-paclitaxel, gemcitabine, and cisplatin), stromal-targeting drugs (calcipotriol and losartan), and an immune checkpoint inhibitor (anti-PD-L1). We developed a set of ordinary differential equations describing changes in tumor size under the influence of cocktails of treatments. Parameter estimation relies on three tumor volume measurements obtained over a 14-day period in a genetically engineered pancreatic cancer model (\n                    <jats:inline-formula>\n                      <jats:alternatives>\n                        <jats:tex-math>$${{Kras}}^{{\\rm{LSL}}-{\\rm{G12D}}}\\,;\\,{{Trp53}}^{{\\rm{LSL}}-{\\rm{R172H}}}\\,;\\,{Pdx1}-{\\rm{Cre}}$$<\/jats:tex-math>\n                        <mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                          <mml:mrow>\n                            <mml:msup>\n                              <mml:mrow>\n                                <mml:mi>K<\/mml:mi>\n                                <mml:mi>r<\/mml:mi>\n                                <mml:mi>a<\/mml:mi>\n                                <mml:mi>s<\/mml:mi>\n                              <\/mml:mrow>\n                              <mml:mrow>\n                                <mml:mstyle>\n                                  <mml:mi>L<\/mml:mi>\n                                  <mml:mi>S<\/mml:mi>\n                                  <mml:mi>L<\/mml:mi>\n                                <\/mml:mstyle>\n                                <mml:mo>-<\/mml:mo>\n                                <mml:mstyle>\n                                  <mml:mi>G<\/mml:mi>\n                                  <mml:mn>12<\/mml:mn>\n                                  <mml:mi>D<\/mml:mi>\n                                <\/mml:mstyle>\n                              <\/mml:mrow>\n                            <\/mml:msup>\n                            <mml:mspace\/>\n                            <mml:mo>;<\/mml:mo>\n                            <mml:mspace\/>\n                            <mml:msup>\n                              <mml:mrow>\n                                <mml:mi>T<\/mml:mi>\n                                <mml:mi>r<\/mml:mi>\n                                <mml:mi>p<\/mml:mi>\n                                <mml:mn>53<\/mml:mn>\n                              <\/mml:mrow>\n                              <mml:mrow>\n                                <mml:mstyle>\n                                  <mml:mi>L<\/mml:mi>\n                                  <mml:mi>S<\/mml:mi>\n                                  <mml:mi>L<\/mml:mi>\n                                <\/mml:mstyle>\n                                <mml:mo>-<\/mml:mo>\n                                <mml:mstyle>\n                                  <mml:mi>R<\/mml:mi>\n                                  <mml:mn>172<\/mml:mn>\n                                  <mml:mi>H<\/mml:mi>\n                                <\/mml:mstyle>\n                              <\/mml:mrow>\n                            <\/mml:msup>\n                            <mml:mspace\/>\n                            <mml:mo>;<\/mml:mo>\n                            <mml:mspace\/>\n                            <mml:mi>P<\/mml:mi>\n                            <mml:mi>d<\/mml:mi>\n                            <mml:mi>x<\/mml:mi>\n                            <mml:mn>1<\/mml:mn>\n                            <mml:mo>-<\/mml:mo>\n                            <mml:mstyle>\n                              <mml:mi>C<\/mml:mi>\n                              <mml:mi>r<\/mml:mi>\n                              <mml:mi>e<\/mml:mi>\n                            <\/mml:mstyle>\n                          <\/mml:mrow>\n                        <\/mml:math>\n                      <\/jats:alternatives>\n                    <\/jats:inline-formula>\n                    ). Our model reproduces tumor growth in all scenarios with an average concordance correlation coefficient (CCC) of 0.99\u2009\u00b1\u20090.01. We conduct leave-one-out predictions (average CCC\u2009=\u20090.74\u2009\u00b1\u20090.06), mouse-specific predictions (average CCC\u2009=\u20090.75\u2009\u00b1\u20090.02), and hybrid, group-informed, mouse-specific predictions (average CCC\u2009=\u20090.85\u2009\u00b1\u20090.04). The developed mathematical model demonstrates high accuracy in fitting the experimental tumor data and a robust ability to predict tumor response to treatment. This approach has important implications for optimizing combination NGC treatment strategies.\n                  <\/jats:p>","DOI":"10.1038\/s41540-025-00593-z","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:34:01Z","timestamp":1762274041000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Modeling tumor dynamics and predicting response to therapies in a murine pancreatic cancer model"],"prefix":"10.1038","volume":"11","author":[{"given":"Krithik","family":"Vishwanath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna G.","family":"Sorace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Yankeelov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto A. B. F.","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"593_CR1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/path.5260","volume":"248","author":"RH Hruban","year":"2019","unstructured":"Hruban, R. H. et al. Why is pancreatic cancer so deadly? The pathologist\u2019s view. J. Pathol. 248, 131\u2013141 (2019).","journal-title":"J. Pathol."},{"key":"593_CR2","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00595-020-02028-0","volume":"50","author":"RJ Torphy","year":"2020","unstructured":"Torphy, R. J., Fujiwara, Y. & Schulick, R. D. Pancreatic cancer treatment: better, but a long way to go. Surg. Today 50, 1117\u20131125 (2020).","journal-title":"Surg. Today"},{"key":"593_CR3","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA A Cancer J. Clin 74, 12\u201349 (2024).","journal-title":"CA A Cancer J. Clin"},{"key":"593_CR4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1158\/0008-5472.CAN-18-3751","volume":"79","author":"H Huang","year":"2019","unstructured":"Huang, H. & Brekken, R. A. The next wave of stroma-targeting therapy in pancreatic cancer. Cancer Res. 79, 328\u2013330 (2019).","journal-title":"Cancer Res."},{"key":"593_CR5","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.3748\/wjg.v27.i18.2105","volume":"27","author":"F Polani","year":"2021","unstructured":"Polani, F., Grierson, P. M. & Lim, K.-H. Stroma-targeting strategies in pancreatic cancer: past lessons, challenges and prospects. World J. Gastroenterol. 27, 2105\u20132121 (2021).","journal-title":"World J. Gastroenterol."},{"key":"593_CR6","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1007\/s00432-020-03332-5","volume":"146","author":"MH Sodergren","year":"2020","unstructured":"Sodergren, M. H. et al. Immunological combination treatment holds the key to improving survival in pancreatic cancer. J. Cancer Res. Clin. Oncol. 146, 2897\u20132911 (2020).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"593_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jbior.2017.11.007","volume":"68","author":"A Adamska","year":"2018","unstructured":"Adamska, A. et al. Molecular and cellular mechanisms of chemoresistance in pancreatic cancer. Adv. Biol. Regul. 68, 77\u201387 (2018).","journal-title":"Adv. Biol. Regul."},{"key":"593_CR8","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M. & Maitra, A. Pancreatic cancer: Advances and challenges. Cell 186, 1729\u20131754 (2023).","journal-title":"Cell"},{"key":"593_CR9","doi-asserted-by":"publisher","first-page":"e22708","DOI":"10.1002\/jbt.22708","volume":"35","author":"K Mortezaee","year":"2021","unstructured":"Mortezaee, K. Enriched cancer stem cells, dense stroma, and cold immunity: interrelated events in pancreatic cancer. J. Biochem. Mol. Toxicol. 35, e22708 (2021).","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"593_CR10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/ags3.12225","volume":"3","author":"T Murakami","year":"2019","unstructured":"Murakami, T. et al. Role of the tumor microenvironment in pancreatic cancer. Ann. Gastroenterol. Surg. 3, 130\u2013137 (2019).","journal-title":"Ann. Gastroenterol. Surg."},{"key":"593_CR11","doi-asserted-by":"publisher","first-page":"688377","DOI":"10.3389\/fonc.2021.688377","volume":"11","author":"DR Principe","year":"2021","unstructured":"Principe, D. R. et al. The current treatment paradigm for pancreatic ductal adenocarcinoma and barriers to therapeutic efficacy. Front. Oncol. 11, 688377 (2021).","journal-title":"Front. Oncol."},{"key":"593_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0858-1","volume":"17","author":"B Ren","year":"2018","unstructured":"Ren, B. et al. Tumor microenvironment participates in metastasis of pancreatic cancer. Mol. Cancer 17, 108 (2018).","journal-title":"Mol. Cancer"},{"key":"593_CR13","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3390\/cancers14040985","volume":"14","author":"S Robatel","year":"2022","unstructured":"Robatel, S. & Schenk, M. Current limitations and novel perspectives in pancreatic cancer treatment. Cancers 14, 985 (2022).","journal-title":"Cancers"},{"key":"593_CR14","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.3390\/cancers14174209","volume":"14","author":"N Skorupan","year":"2022","unstructured":"Skorupan, N., Palestino Dominguez, M., Ricci, S. L. & Alewine, C. Clinical strategies targeting the tumor microenvironment of pancreatic ductal adenocarcinoma. Cancers 14, 4209 (2022).","journal-title":"Cancers"},{"key":"593_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41251-9","volume":"9","author":"B Yoo","year":"2019","unstructured":"Yoo, B. et al. RNAi-mediated PD-L1 inhibition for pancreatic cancer immunotherapy. Sci. Rep. 9, 4712 (2019).","journal-title":"Sci. Rep."},{"key":"593_CR16","doi-asserted-by":"publisher","first-page":"101807","DOI":"10.1016\/j.isci.2020.101807","volume":"23","author":"AS Kazerouni","year":"2020","unstructured":"Kazerouni, A. S. et al. Integrating quantitative assays with biologically based mathematical modeling for predictive oncology. iScience 23, 101807 (2020).","journal-title":"iScience"},{"key":"593_CR17","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2174\/1568026620666200101095641","volume":"20","author":"P Dogra","year":"2020","unstructured":"Dogra, P. et al. Mathematical modeling to address challenges in pancreatic cancer. Curr. Top. Medicinal Chem. 20, 367\u2013376 (2020).","journal-title":"Curr. Top. Medicinal Chem."},{"key":"593_CR18","doi-asserted-by":"publisher","first-page":"e1003231","DOI":"10.1371\/journal.pcbi.1003231","volume":"9","author":"JJ Lee","year":"2013","unstructured":"Lee, J. J., Huang, J., England, C. G., McNally, L. R. & Frieboes, H. B. Predictive modeling of in vivo response to gemcitabine in pancreatic cancer. PLoS Comput. Biol. 9, e1003231 (2013).","journal-title":"PLoS Comput. Biol."},{"key":"593_CR19","doi-asserted-by":"publisher","first-page":"e1010104","DOI":"10.1371\/journal.pcbi.1010104","volume":"19","author":"AL Jenner","year":"2023","unstructured":"Jenner, A. L. et al. Examining the efficacy of localised gemcitabine therapy for the treatment of pancreatic cancer using a hybrid agent-based model. PLoS Comput. Biol. 19, e1010104 (2023).","journal-title":"PLoS Comput. Biol."},{"key":"593_CR20","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.3390\/math10193557","volume":"10","author":"AS Bratus","year":"2022","unstructured":"Bratus, A. S. et al. Mathematical model of pancreatic cancer cell dynamics considering the set of sequential mutations and interaction with the immune system. Mathematics 10, 3557 (2022).","journal-title":"Mathematics"},{"key":"593_CR21","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s11538-019-00591-3","volume":"81","author":"X Hu","year":"2019","unstructured":"Hu, X., Ke, G. & Jang, S. R.-J. Modeling pancreatic cancer dynamics with immunotherapy. Bull. Math. Biol. 81, 1885\u20131915 (2019).","journal-title":"Bull. Math. Biol."},{"key":"593_CR22","doi-asserted-by":"crossref","unstructured":"Konishi, S. & Kitagawa, G. Information Criteria and Statistical Modeling (Springer Science & Business Media, 2008).","DOI":"10.1007\/978-0-387-71887-3"},{"key":"593_CR23","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/02664761003692449","volume":"38","author":"A Yuan","year":"2011","unstructured":"Yuan, A. et al. Bayesian\u2013frequentist hybrid model with application to the analysis of gene copy number changes. J. Appl. Stat. 38, 987\u20131005 (2011).","journal-title":"J. Appl. Stat."},{"key":"593_CR24","doi-asserted-by":"publisher","first-page":"e70144","DOI":"10.1002\/sim.70144","volume":"44","author":"B Duputel","year":"2025","unstructured":"Duputel, B., Stallard, N., Montestruc, F., Zohar, S. & Ursino, M. A seamless hybrid phase II\/III design with bayesian interim subgroup selection. Stat. Med. 44, e70144 (2025).","journal-title":"Stat. Med."},{"key":"593_CR25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/07474946.2019.1648919","volume":"38","author":"Z Djeridi","year":"2019","unstructured":"Djeridi, Z. & Merabet, H. A hybrid Bayesian-frequentist predictive design for monitoring multi-stage clinical trials. Sequential Anal. 38, 301\u2013317 (2019).","journal-title":"Sequential Anal."},{"key":"593_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-024-00638-0","volume":"18","author":"G Han","year":"2024","unstructured":"Han, G. et al. Bayesian-frequentist hybrid inference framework for single-cell RNA-seq analyses. Hum. Genomics 18, 69 (2024).","journal-title":"Hum. Genomics"},{"key":"593_CR27","unstructured":"Complex clinical trials \u2013 questions and answers. Questions and answers EMA\/298712\/2022, European Medicines Agency https:\/\/health.ec.europa.eu\/system\/files\/2022-06\/medicinal_qa_complex_clinical-trials_en.pdf (2022)."},{"key":"593_CR28","unstructured":"of Health, U. D. & Services, H. Adaptive designs for clinical trials of drugs and biologics (FDA, 2019)."},{"key":"593_CR29","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1200\/JCO.2008.21.0807","volume":"27","author":"L Claret","year":"2009","unstructured":"Claret, L. et al. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase ii tumor dynamics. J. Clin. Oncol. 27, 4103\u20134108 (2009).","journal-title":"J. Clin. Oncol."},{"key":"593_CR30","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/cas.14346","volume":"111","author":"Y Miyai","year":"2020","unstructured":"Miyai, Y., Esaki, N., Takahashi, M. & Enomoto, A. Cancer-associated fibroblasts that restrain cancer progression: hypotheses and perspectives. Cancer Sci. 111, 1047\u20131057 (2020).","journal-title":"Cancer Sci."},{"key":"593_CR31","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1158\/0008-5472.CAN-21-4141","volume":"82","author":"L Jenkins","year":"2022","unstructured":"Jenkins, L. et al. Cancer-associated fibroblasts suppress CD8+T-cell infiltration and confer resistance to immune-checkpoint blockade. Cancer Res. 82, 2904\u20132917 (2022).","journal-title":"Cancer Res."},{"key":"593_CR32","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1172\/JCI130809","volume":"130","author":"MS Williams","year":"2020","unstructured":"Williams, M. S. et al. A stress-responsive enhancer induces dynamic drug resistance in acute myeloid leukemia. J. Clin. Investig. 130, 1217\u20131232 (2020).","journal-title":"J. Clin. Investig."},{"key":"593_CR33","first-page":"11","volume":"4","author":"M Morishita","year":"2008","unstructured":"Morishita, M. & Leonard, R. C. Capecitabine and docetaxel combination for the treatment of breast cancer. Women\u2019s. Health 4, 11\u201322 (2008).","journal-title":"Women\u2019s. Health"},{"key":"593_CR34","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.3390\/cancers3033114","volume":"3","author":"GM Weir","year":"2011","unstructured":"Weir, G. M., Liwski, R. S. & Mansour, M. Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines. Cancers 3, 3114\u20133142 (2011).","journal-title":"Cancers"},{"key":"593_CR35","doi-asserted-by":"publisher","first-page":"eabh0363","DOI":"10.1126\/sciadv.abh0363","volume":"7","author":"KJ Murphy","year":"2021","unstructured":"Murphy, K. J. et al. Intravital imaging technology guides Fak-mediated priming in pancreatic cancer precision medicine according to Merlin status. Sci. Adv. 7, eabh0363 (2021).","journal-title":"Sci. Adv."},{"key":"593_CR36","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3390\/genes12020208","volume":"12","author":"A Majchrzak-Celi\u0144ska","year":"2021","unstructured":"Majchrzak-Celi\u0144ska, A., Warych, A. & Szoszkiewicz, M. Novel approaches to epigenetic therapies: from drug combinations to epigenetic editing. Genes 12, 208 (2021).","journal-title":"Genes"},{"key":"593_CR37","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.3390\/cancers14205071","volume":"14","author":"A Amiama-Roig","year":"2022","unstructured":"Amiama-Roig, A., Verdugo-Sivianes, E. M., Carnero, A. & Blanco, J.-R. Chronotherapy: circadian rhythms and their influence in cancer therapy. Cancers 14, 5071 (2022).","journal-title":"Cancers"},{"key":"593_CR38","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s10237-019-01219-0","volume":"19","author":"J Chen","year":"2020","unstructured":"Chen, J., Weihs, D. & Vermolen, F. J. Computational modeling of therapy on pancreatic cancer in its early stages. Biomech. Modeling Mechanobiol. 19, 427\u2013444 (2020).","journal-title":"Biomech. Modeling Mechanobiol."},{"key":"593_CR39","doi-asserted-by":"publisher","first-page":"115484","DOI":"10.1016\/j.cma.2022.115484","volume":"402","author":"EABF Lima","year":"2022","unstructured":"Lima, E. A. B. F., Wyde, R. A. F., Sorace, A. G. & Yankeelov, T. E. Optimizing combination therapy in a murine model of HER2+ breast cancer. Comp. Methods Appl. Mech. Eng. 402, 115484 (2022).","journal-title":"Comp. Methods Appl. Mech. Eng."},{"key":"593_CR40","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41575-018-0005-x","volume":"15","author":"JP Neoptolemos","year":"2018","unstructured":"Neoptolemos, J. P. et al. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat. Rev. Gastroenterol. Hepatol. 15, 333\u2013348 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"593_CR41","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s00366-023-01873-0","volume":"40","author":"G Lorenzo","year":"2024","unstructured":"Lorenzo, G. et al. A global sensitivity analysis of a mechanistic model of neoadjuvant chemotherapy for triple negative breast cancer constrained by in vitro and in vivo imaging data. Eng. Comp. 40, 1469\u20131499 (2024).","journal-title":"Eng. Comp."},{"key":"593_CR42","doi-asserted-by":"publisher","first-page":"2321769","DOI":"10.1080\/15384047.2024.2321769","volume":"25","author":"HJM Miniere","year":"2024","unstructured":"Miniere, H. J. M. et al. A mathematical model for predicting the spatiotemporal response of breast cancer cells treated with doxorubicin. Cancer Biol. Ther. 25, 2321769 (2024).","journal-title":"Cancer Biol. Ther."},{"key":"593_CR43","unstructured":"Gupta, M. et al. Effect of stroma-directed drugs in combination with chemotherapy against pancreatic cancer- a preclinical study. bioRxiv https:\/\/www.biorxiv.org\/content\/early\/2024\/12\/25\/2024.12.24.630138 (2024)."},{"key":"593_CR44","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","volume":"7","author":"SR Hingorani","year":"2005","unstructured":"Hingorani, S. R. et al. Trp53r172h and krasg12d cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469\u2013483 (2005).","journal-title":"Cancer Cell"},{"key":"593_CR45","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1158\/1078-0432.CCR-18-2276","volume":"25","author":"J Cao","year":"2019","unstructured":"Cao, J. et al. Dynamic contrast-enhanced MRI detects responses to stroma-directed therapy in mouse models of pancreatic ductal adenocarcinoma. Clin. Cancer Res. 25, 2314\u20132322 (2019).","journal-title":"Clin. Cancer Res."},{"key":"593_CR46","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.3390\/cancers14164017","volume":"14","author":"M Romanello Joaquim","year":"2022","unstructured":"Romanello Joaquim, M. et al. Dwi metrics differentiating benign intraductal papillary mucinous neoplasms from invasive pancreatic cancer: a study in gem models. Cancers 14, 4017 (2022).","journal-title":"Cancers"},{"key":"593_CR47","first-page":"14","volume":"73","author":"JW Lee","year":"2016","unstructured":"Lee, J. W., Komar, C. A., Bengsch, F., Graham, K. & Beatty, G. L. Genetically engineered mouse models of pancreatic cancer: the kpc model (lsl-krasg12d\/+; lsl-trp53r172h\/+; pdx-1-cre), its variants, and their application in immuno-oncology drug discovery. Curr. Protoc. Pharmacol. 73, 14\u201339 (2016).","journal-title":"Curr. Protoc. Pharmacol."},{"key":"593_CR48","doi-asserted-by":"crossref","unstructured":"Desai, N. Nanoparticle albumin-bound paclitaxel (abraxane\u00ae). Albumin in medicine: Pathological and clinical applications 101\u2013119 (Springer, 2016).","DOI":"10.1007\/978-981-10-2116-9_6"},{"key":"593_CR49","doi-asserted-by":"publisher","first-page":"17625","DOI":"10.3934\/mbe.2023783","volume":"20","author":"EA Lima","year":"2023","unstructured":"Lima, E. A. et al. Predicting response to combination evofosfamide and immunotherapy under hypoxic conditions in murine models of colon cancer. Math. Biosci. Eng. MBE 20, 17625 (2023).","journal-title":"Math. Biosci. Eng. MBE"},{"key":"593_CR50","doi-asserted-by":"publisher","first-page":"e1008845","DOI":"10.1371\/journal.pcbi.1008845","volume":"17","author":"EA Lima","year":"2021","unstructured":"Lima, E. A. et al. Bayesian calibration of a stochastic, multiscale agent-based model for predicting in vitro tumor growth. PLoS Comput. Biol. 17, e1008845 (2021).","journal-title":"PLoS Comput. Biol."},{"key":"593_CR51","first-page":"407","volume":"1","author":"IM Sobo\u013a","year":"1993","unstructured":"Sobo\u013a, I. M. Sensitivity estimates for nonlinear mathematical models. Math. Model. Comput. Exp. 1, 407 (1993).","journal-title":"Math. Model. Comput. Exp."},{"key":"593_CR52","doi-asserted-by":"crossref","unstructured":"Saltelli, A. et al. Global Sensitivity Analysis: The Primer (Wiley, 2008).","DOI":"10.1002\/9780470725184"},{"key":"593_CR53","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.envsoft.2019.01.012","volume":"114","author":"A Saltelli","year":"2019","unstructured":"Saltelli, A. et al. Why so many published sensitivity analyses are false: a systematic review of sensitivity analysis practices. Environ. Model. Softw. 114, 29\u201339 (2019).","journal-title":"Environ. Model. Softw."},{"key":"593_CR54","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.cpc.2009.09.018","volume":"181","author":"A Saltelli","year":"2010","unstructured":"Saltelli, A. et al. Variance based sensitivity analysis of model output. Design and estimator for the total sensitivity index. Computer Phys. Commun. 181, 259\u2013270 (2010).","journal-title":"Computer Phys. Commun."},{"key":"593_CR55","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1158\/0008-5472.CAN-22-1329","volume":"82","author":"C Wu","year":"2022","unstructured":"Wu, C. et al. MRI-based digital models forecast patient-specific treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer. Cancer Res. 82, 3394\u20133404 (2022).","journal-title":"Cancer Res."},{"key":"593_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-87887-4","volume":"11","author":"DA Hormuth","year":"2021","unstructured":"Hormuth, D. A., Al Feghali, K. A., Elliott, A. M., Yankeelov, T. E. & Chung, C. Image-based personalization of computational models for predicting response of high-grade glioma to chemoradiation. Sci. Rep. 11, 8520 (2021).","journal-title":"Sci. Rep."},{"key":"593_CR57","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1158\/2767-9764.CRC-23-0449","volume":"4","author":"G Lorenzo","year":"2024","unstructured":"Lorenzo, G. et al. A pilot study on patient-specific computational forecasting of prostate cancer growth during active surveillance using an imaging-informed biomechanistic model. Cancer Res. Commun. 4, 617\u2013633 (2024).","journal-title":"Cancer Res. Commun."},{"key":"593_CR58","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1086\/670067","volume":"125","author":"D Foreman-Mackey","year":"2013","unstructured":"Foreman-Mackey, D., Hogg, D. W., Lang, D. & Goodman, J. Emcee: The MCMC Hammer. Publ. Astronom. Soc. Pac. 125, 306 (2013).","journal-title":"Publ. Astronom. Soc. Pac."}],"container-title":["npj Systems Biology and Applications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41540-025-00593-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-025-00593-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-025-00593-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:05:36Z","timestamp":1762319136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41540-025-00593-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["593"],"URL":"https:\/\/doi.org\/10.1038\/s41540-025-00593-z","relation":{},"ISSN":["2056-7189"],"issn-type":[{"value":"2056-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"26 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"123"}}